Pharmaceutical intermediates
Eldecalcitol Intermediates
6 pharmaceutical intermediates for Eldecalcitol. Indication: Postmenopausal osteoporosis; Osteoporosis.
About Eldecalcitol
- Originator
- Chugai Pharmaceutical Co., Ltd
- Indication
- Postmenopausal osteoporosis; Osteoporosis
Available intermediates
6 intermediates currently listed for Eldecalcitol. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| de-A,B-25-hydroxycholestan-8β-ol | 66774-84-3 | / | / |
| (1R,3aR,7aR)-1-((R)-6-hydroxy-6-Methylheptan-2-yl)-7a-Methylhexahydro-1H-inden-4(2H)-one | 70550-73-1 | / | / |
| 4H-Inden-4-one, 1-[1,5-dimethyl-5-[(triethylsilyl)oxy]hexyl]octahydro-7a-methyl-, [1R-[1α(R*),3aβ,7aα]]- | 144848-24-8 | / | / |
| Eldecalcitol interMediates | 200636-42-6 | / | / |
| Phosphine oxide, [(2Z)-2-[(3R,4R,5R)-3,5-bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-4-[3-[[(1,1-diMethylethyl)diMethylsilyl]oxy]propoxy]-2-Methylenecyclohexylidene]ethyl]diphenyl- | 200636-54-0 | / | / |
| Phosphine oxide, [(2Z)-2-[(3R,4R,5R)-2-methylene-3,5-bis[(triethylsilyl)oxy]-4-[3-[(triethylsilyl)oxy]propoxy]cyclohexylidene]ethyl]diphenyl- | 2189732-17-8 | / | / |
Building toward Eldecalcitol?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →